Ocugen, Inc. (OCGN) vs Prelude Therapeutics Incorporated (PRLD)

Ocugen, Inc. and Prelude Therapeutics Incorporated are both Biotechnology companies. Ocugen, Inc. and Prelude Therapeutics Incorporated are of similar size ($339.1M and $318.4M). Prelude Therapeutics Incorporated has the higher net margin (−269.8% vs −1,786.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Prelude Therapeutics Incorporated leads on 10 and Ocugen, Inc. on 3.

Valuation

Metric OCGN PRLD Biotechnology median
P/E n/m n/m 7.88
P/S 75.43 17.02 11.47
P/B n/m 2.85 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 53.96 10.26 10.73
Earnings yield (25.49%) (18.81%) (28.84%)
Free cash flow yield (17.66%) (8.73%) (23.03%)

Profitability

Metric OCGN PRLD Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (1,504.43%) (300.56%) 0.00%
Net margin (1,786.27%) (269.75%) 0.00%
Free cash flow margin (1,332.36%) (148.30%) 0.00%
Return on equity 1,211.66% (57.73%) (57.72%)
Return on assets (92.03%) (39.76%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric OCGN PRLD Biotechnology median
Revenue growth (TTM) (3.66%) — 5.64%
EPS growth (last fiscal year) (15.00%) 23.21% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric OCGN PRLD Biotechnology median
Debt to equity (0.11) 0.00 0.00
Current ratio 0.80 4.07 4.73
Net debt to EBITDA (0.17) 1.00 0.96

Dividend

Metric OCGN PRLD Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric OCGN PRLD Biotechnology median
Market cap 339.11m 318.42m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack